SHAREHOLDER ALERT: Brower Piven Encourages Investors With Losses Over $100,000 In Vertex Pharmaceuticals Incorporated To Cont...
July 22 2014 - 5:44PM
The securities litigation law firm of Brower Piven, A Professional
Corporation, announces that a class action lawsuit has been
commenced in the United States District Court for the District of
Massachusetts on behalf of purchasers of Vertex Pharmaceuticals
Incorporated ("Vertex" or the "Company") (Nasdaq:VRTX) common stock
during the period between May 7, 2012 and May 29, 2012, inclusive
(the "Class Period"), and informs investors who wish to become
proactively involved in the litigation that they have until July
28, 2014 to seek appointment as lead plaintiff.
If you have suffered a loss from investment in Vertex common
stock purchased on or after May 7, 2012 and held through the
revelation of negative information during and/or at the end of the
Class Period, as described below, and would like to learn more
about this lawsuit and your ability to participate as a lead
plaintiff, without cost or obligation to you, please visit our
website at http://www.browerpiven.com/currentsecuritiescases.html.
You may also request more information by contacting Brower Piven
either by email at hoffman@browerpiven.com or by telephone at (410)
415-6616.
No class has yet been certified in the above action. Members of
the Class will be represented by the lead plaintiff and counsel
chosen by the lead plaintiff. If you wish to choose counsel to
represent you and the Class, you must apply to be appointed lead
plaintiff no later than July 28, 2014 and be selected by the
Court. The lead plaintiff will direct the litigation and
participate in important decisions including whether to accept a
settlement and how much of a settlement to accept for the Class in
the action. The lead plaintiff will be selected from among
applicants claiming the largest loss from investment in Company
units during the Class Period.
The complaint accuses the defendants of violations of the
Securities Exchange Act of 1934 by virtue of the defendants'
misrepresentation during the Class Period regarding the positive
nature of the interim data from its Phase 2 study of VX-809 and
Kalydeco. According to the complaint, following the May 29, 2012
announcement by the Company that the exceptional results of the
Phase 2 study of the two medications were grossly over-stated, the
value of Vertex shares declined significantly.
Attorneys at Brower Piven have extensive experience in
litigating securities and other class action cases and have been
advocating for the rights of shareholders since the 1980s. If
you choose to retain counsel, you may retain Brower Piven without
financial obligation or cost to you, or you may retain other
counsel of your choice. You need take no action at this time
to be a member of the class.
CONTACT: Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
hoffman@browerpiven.com
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Sep 2023 to Sep 2024